Pay in 4 interest-free payments of $6.60 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
For Lilly internally, retatrutide moves from a hopeful pipeline asset to a pillar of the company's late-decade franchise alongside tirzepatide, which still dominates the dual-agonist segment, and oral orforglipron, which has its own ATTAIN-1 data showing 12.4% loss in non-diabetic adults
By targeting three distinct hormonal pathways, it offers a multi-dimensional approach to metabolic health and weight regulation
Treasure Island (FL): StatPearls Publishing (2025)
8 Union Territories All Vacant 700+ Cities/Taluks/Villages Open Reserve Your Territory Apply For Franchise Claim your monopoly territory today
US$ 22.30
US$ 21.35
US$ 20.14
